Academic Bibliography

 Search 200 years of publications by Ghent University researchers.
Advanced search
2 files | 1.36 MB
Add to list
  1. Search results
  2. Inflammasomes and IL-1 family cytokin...

Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection : from prognostic marker to therapeutic agent

Jozefien Declercq (UGent) , Elisabeth De Leeuw (UGent) and Bart Lambrecht (UGent)
(2022) CYTOKINE. 157.
Author
Organization
Project
Abstract
Despite global vaccination programs, infections with severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) continue to cause severe disease with significant morbidity and mortality. Severe coronavirus disease 2019 (COVID-19) is characterized by an exuberant inflammatory response in the lung leading to acute lung injury and consequent gas exchange problems. Complete insights in this hyperinflammatory response are still lacking. However, a thorough understanding of immunopathogenesis of severe COVID-19 is needed to not only develop personalized targeted therapies, but also to identify biomarkers that predict disease outcome and therapeutic responses. Here we review the current evidence that SARS-CoV-2 activates the inflammasome, which is an intracellular multiprotein complex that leads to the activation and secretion of the interleukin (IL)-1 family cytokines, IL-1 beta and IL-18, and to a lytic form of cell death, called pyroptosis. Further we discuss the contribution of inflammasomes and IL-1 family cytokines to the immunopathogenesis of COVID-19 and its clinical implications.
Keywords
SARS-CoV-2, COVID-19, IL-1B, IL-18, Inflammasome, NLRP3, NLRP3 INFLAMMASOME, INFLUENZA-VIRUS, SEVERE COVID-19, I INTERFERON, ACTIVATION, RNA, IMMUNITY, INTERLEUKIN-1, INHIBITION, IL-1-BETA

Downloads

  • Download
    (...).pdf
    • full text (Published version)
    • |
    • UGent only
    • |
    • application/octet-stream
    • |
    • 893.79 KB
  • Download
    AAM Declercq.pdf
    • full text (Accepted manuscript)
    • |
    • open access
    • |
    • PDF
    • |
    • 468.93 KB

Citation

Please use this url to cite or link to this publication:

MLA
Declercq, Jozefien, et al. “Inflammasomes and IL-1 Family Cytokines in SARS-CoV-2 Infection : From Prognostic Marker to Therapeutic Agent.” CYTOKINE, vol. 157, 2022, doi:10.1016/j.cyto.2022.155934.
APA
Declercq, J., De Leeuw, E., & Lambrecht, B. (2022). Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection : from prognostic marker to therapeutic agent. CYTOKINE, 157. https://doi.org/10.1016/j.cyto.2022.155934
Chicago author-date
Declercq, Jozefien, Elisabeth De Leeuw, and Bart Lambrecht. 2022. “Inflammasomes and IL-1 Family Cytokines in SARS-CoV-2 Infection : From Prognostic Marker to Therapeutic Agent.” CYTOKINE 157. https://doi.org/10.1016/j.cyto.2022.155934.
Chicago author-date (all authors)
Declercq, Jozefien, Elisabeth De Leeuw, and Bart Lambrecht. 2022. “Inflammasomes and IL-1 Family Cytokines in SARS-CoV-2 Infection : From Prognostic Marker to Therapeutic Agent.” CYTOKINE 157. doi:10.1016/j.cyto.2022.155934.
Vancouver
1.
Declercq J, De Leeuw E, Lambrecht B. Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection : from prognostic marker to therapeutic agent. CYTOKINE. 2022;157.
IEEE
[1]
J. Declercq, E. De Leeuw, and B. Lambrecht, “Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection : from prognostic marker to therapeutic agent,” CYTOKINE, vol. 157, 2022.
@article{8762876,
  abstract     = {{Despite global vaccination programs, infections with severe acute respiratory syndrome coronavirus-2 (SARSCoV-2) continue to cause severe disease with significant morbidity and mortality. Severe coronavirus disease 2019 (COVID-19) is characterized by an exuberant inflammatory response in the lung leading to acute lung injury and consequent gas exchange problems. Complete insights in this hyperinflammatory response are still lacking. However, a thorough understanding of immunopathogenesis of severe COVID-19 is needed to not only develop personalized targeted therapies, but also to identify biomarkers that predict disease outcome and therapeutic responses. Here we review the current evidence that SARS-CoV-2 activates the inflammasome, which is an intracellular multiprotein complex that leads to the activation and secretion of the interleukin (IL)-1 family cytokines, IL-1 beta and IL-18, and to a lytic form of cell death, called pyroptosis. Further we discuss the contribution of inflammasomes and IL-1 family cytokines to the immunopathogenesis of COVID-19 and its clinical implications.}},
  articleno    = {{155934}},
  author       = {{Declercq, Jozefien and De Leeuw, Elisabeth and Lambrecht, Bart}},
  issn         = {{1043-4666}},
  journal      = {{CYTOKINE}},
  keywords     = {{SARS-CoV-2,COVID-19,IL-1B,IL-18,Inflammasome,NLRP3,NLRP3 INFLAMMASOME,INFLUENZA-VIRUS,SEVERE COVID-19,I INTERFERON,ACTIVATION,RNA,IMMUNITY,INTERLEUKIN-1,INHIBITION,IL-1-BETA}},
  language     = {{eng}},
  pages        = {{10}},
  title        = {{Inflammasomes and IL-1 family cytokines in SARS-CoV-2 infection : from prognostic marker to therapeutic agent}},
  url          = {{http://doi.org/10.1016/j.cyto.2022.155934}},
  volume       = {{157}},
  year         = {{2022}},
}
Altmetric
View in Altmetric
Web of Science
Times cited: